Anti-EGF antibodies generated by vaccination significantly improve the activity of kinase inhibitors in preclinical models
Por:
Codony-Servat, J, Garcia-Roman, S, Molina-Vila, MA, Bertran-Alamillo, J, Gimenez-Capitan, A, Viteri, S, Cardona, AF, Rodriguez, D, Cobo, M, Reguart, N, Karachaliou, N, d'Hondt, E and Rosell, R
Publicada:
1 jul 2019
Resumen:
Filiaciones:
Codony-Servat, J:
Pangaea Oncol, Barcelona, Spain
Garcia-Roman, S:
Pangaea Oncol, Barcelona, Spain
Molina-Vila, MA:
Pangaea Oncol, Barcelona, Spain
Bertran-Alamillo, J:
Pangaea Oncol, Barcelona, Spain
Gimenez-Capitan, A:
Pangaea Oncol, Barcelona, Spain
Viteri, S:
IOR, Barcelona, Spain
Cardona, AF:
Fdn Santa Fe Bogota, Inst Oncol, Clin & Translat Oncol Grp, Bogota, Colombia
Rodriguez, D:
Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain
Cobo, M:
Hosp Univ Reg Malaga, Malaga, Spain
Reguart, N:
Hosp Clin Barcelona, Barcelona, Spain
Karachaliou, N:
IOR, Barcelona, Spain
d'Hondt, E:
Bioven, Aberdeen, Scotland
:
Inst Catala Oncol, Badalona, Spain
Inst Invest Ciencies Salut Germans Trias & Pujol, Badalona, Spain
|